Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current HIV Research

• Publication date

  2015-12-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1570162X1401151102143222PMID 26531764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Combination Antiretroviral Therapies on the Risk of Myocardial Infarction Among HIV Patients

  2014cited by this paper
• Comparison of Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir and Tenofovir: The Nucleoside Inflammation, Coagulation and Endothelial Function (Nice) Study

  2014cited by this paper
• Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study

  2014cited by this paper
• Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan

  2014cited by this paper
• In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients

  2013cited by this paper
• Correlates of Elevated Interleukin-6 and C-Reactive Protein in Persons With or at High Risk for HCV and HIV Infections

  2013cited by this paper
• The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study

  2013cited by this paper
• Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens.

  2012cited by this paper
• Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

  2012cited by this paper
• Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

  2012cited by this paper
• Renal Toxicity Associated With Antiretroviral Therapy

  2012cited by this paper
• Premature age-related comorbidities among HIV-infected persons compared with the general population.

  2011cited by this paper
• Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir

  2011cited by this paper
• No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

  2011cited by this paper
• Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case–Control Study Using Québec's Public Health Insurance Database

  2011cited by this paper
• The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study

  2011cited by this paper
• Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.

  2011cited by this paper
• Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study

  2010cited by this paper
• Abacavir and risk of myocardial infarction in HIV‐infected patients on highly active antiretroviral therapy: a population‐based nationwide cohort study

  2010cited by this paper
• Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

  2010cited by this paper
• Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

  2010cited by this paper
• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  2010cited by this paper
• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  2010cited by this paper
• Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

  2010cited by this paper
• Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects

  2009cited by this paper
• How much is too much? Interleukin-6 and its signalling in atherosclerosis

  2009cited by this paper
• Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells.

  2009cited by this paper
• Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

  2009cited by this paper
• HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy

  2009cited by this paper
• Regulatory T Cells and HIV-1 Infection

  2008cited by this paper
• Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection

  2008cited by this paper
• C-reactive protein: a poor marker of cardiovascular disease risk in HIV+ populations with a high prevalence of elevated serum transaminases

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

  2008cited by this paper
• Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

  2006cited by this paper
• Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate

  2006cited by this paper
• C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.

  2001cited by this paper

• Targeting SIRT-1/AMPK/Nrf2 Signaling Pathway by Tenofovir Protected Against Cyclophosphamide-Induced Nephrotoxicity and Cardiotoxicity in Rats

  2025cites this paper
• Persistent inflammatory activation in people living with HIV. Involvement in atherosclerosis

  2025cites this paper
• Effects of tenofovir on telomeres, telomerase and T cell maturational subset distribution in long-term aviraemic HIV-infected adults.

  2022cites this paper
• Plasma sVCAM‐1, antiretroviral therapy and mortality in HIV‐1‐infected West African adults

  2022cites this paper
• Growth arrest-specific 6 protein in HIV-infected patients: Determination of plasma level and different antiretroviral regimens.

  2021cites this paper
• The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.

  2020cites this paper
• Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.

  2020cites this paper
• The Effect of Antiretroviral Therapy on IL-6, IL-1β, TNF-α, IFN-γ Levels and their Relationship with HIV-RNA and CD4+ T Cells in HIV Patients.

  2020cites this paper
• Does choice of antiretroviral drugs matter for inflammation?

  2019cites this paper
• ICAM-1 in HIV infection and underlying mechanisms.

  2019cites this paper
• Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

  2018cites this paper
• Inflammation, Immune Activation, and Antiretroviral Therapy in HIV

  2017cites this paper
• High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients.

  2017cites this paper
• HIV Infection and Myocardial Infarction.

  2016cites this paper
• Current topics in HIV pathogenesis, part 2: Inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects.

  2016cites this paper
• Untangling the Gordian knot of HIV, stress, and cognitive impairment

  2016cites this paper
• Online solid phase extraction and liquid chromatography-mass spectrometric determination of nucleoside drugs in plasma.

  2016cites this paper